4 research outputs found
Venous thromboembolism-related mortality and morbidity in King Fahd General Hospital, Jeddah, Kingdom of Saudi Arabia
Background: Venous thromboembolism (VTE) is a serious and underestimated potentially fatal disease with an effective prophylactic antithrombotic therapy that is usually underused.
Objectives: The primary study objective is to determine the percentage of VTE patients who received prophylactic antithrombotic therapy according to ACCP guidelines. Secondary study objectives are determining prevalence of confirmed VTE mortality among all cause hospital mortalities, measuring adherence to anticoagulation treatment after discharge and number of VTE events among those patients.
Methods: During the period from first of July 2008 till 30 of June 2009, we collected all hospital deaths, all patients with confirmed VTE diagnosis at King Fahd General Hospital, Jeddah, Kingdom of Saudi Arabia. Only patients with confirmed VTE diagnosis were included in the analysis.
Results: Five hundred cases with clinical diagnosis of VTE were identified. Out of them 178 were confirmed to be VTE. 36.5% of them received prophylactic antithrombotic therapy. Case fatality rate was 20.8% representing 1.9% of hospital deaths. Case fatality rate was 31% and 3.1% for patients who did not receive thromboprophylaxis and patients who received it, respectively ( P < 0.0001). 66.3% and 33.7% of confirmed VTE cases occurred in surgical and medical patients respectively. Only 44.1% of surgical patients and 21.7% of medical patients received prophylaxis ( P < 0.01). Case fatality rate is 11% for surgical patients and 40% for medical patients (P < 0.001). Of 141 survived cases, 118 (83.7%) were adherent to anticoagulation therapy after discharge.
Conclusions: VTE prophylaxis guideline is not properly implemented and extremely underutilized. Mortality from VTE is significantly higher in patients who did not receive VTE prophylaxis. In the absence of regular post-mortem practice VTE related mortality rate would be difficult to estimate and likely will be underestimated. Health authorities should enforce VTE prophylaxis guideline within the healthcare system
A new risk assessment model for VTE derived from a prospective multicenter longitudinal study for the evaluation of VTE risk in ambulatory cancer patients: The COMPASS cancer study.
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.
COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
COVID-19 is also manifested with hypercoagulability, pulmonary
intravascular coagulation, microangiopathy, and venous thromboembolism
(VTE) or arterial thrombosis. Predisposing risk factors to severe
COVID-19 are male sex, underlying cardiovascular disease, or
cardiovascular risk factors including noncontrolled diabetes mellitus or
arterial hypertension, obesity, and advanced age. The VAS-European
Independent Foundation in Angiology/Vascular Medicine draws attention to
patients with vascular disease (VD) and presents an integral strategy
for the management of patients with VD or cardiovascular risk factors
(VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary
health care network for patients with VD-CVR for identification of
patients with VD-CVR in the community and patients' education for
disease symptoms, use of eHealth technology, adherence to the
antithrombotic and vascular regulating treatments, and (2) close medical
follow-up for efficacious control of VD progression and prompt
application of physical and social distancing measures in case of new
epidemic waves. For patients with VD-CVR who receive home treatment for
COVID-19, VAS recommends assessment for (1) disease worsening risk and
prioritized hospitalization of those at high risk and (2) VTE risk
assessment and thromboprophylaxis with rivaroxaban, betrixaban, or
low-molecular-weight heparin (LMWH) for those at high risk. For
hospitalized patients with VD-CVR and COVID-19, VAS recommends (1)
routine thromboprophylaxis with weight-adjusted intermediate doses of
LMWH (unless contraindication); (2) LMWH as the drug of choice over
unfractionated heparin or direct oral anticoagulants for the treatment
of VTE or hypercoagulability; (3) careful evaluation of the risk for
disease worsening and prompt application of targeted antiviral or
convalescence treatments; (4) monitoring of D-dimer for optimization of
the antithrombotic treatment; and (5) evaluation of the risk of VTE
before hospital discharge using the IMPROVE-D-dimer score and prolonged
post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH